WO2022177520A1 - Trousse d'analyse d'urine et son mode d'utilisation - Google Patents

Trousse d'analyse d'urine et son mode d'utilisation Download PDF

Info

Publication number
WO2022177520A1
WO2022177520A1 PCT/TR2021/050520 TR2021050520W WO2022177520A1 WO 2022177520 A1 WO2022177520 A1 WO 2022177520A1 TR 2021050520 W TR2021050520 W TR 2021050520W WO 2022177520 A1 WO2022177520 A1 WO 2022177520A1
Authority
WO
WIPO (PCT)
Prior art keywords
urine
tube
test kit
virus
urine test
Prior art date
Application number
PCT/TR2021/050520
Other languages
English (en)
Inventor
Mehmet Serhan KURTULMUS
Original Assignee
Kurtulmus Mehmet Serhan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kurtulmus Mehmet Serhan filed Critical Kurtulmus Mehmet Serhan
Publication of WO2022177520A1 publication Critical patent/WO2022177520A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B10/007—Devices for taking samples of body liquids for taking urine samples
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L1/00—Enclosures; Chambers
    • B01L1/52—Transportable laboratories; Field kits
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/02—Adapting objects or devices to another
    • B01L2200/026—Fluid interfacing between devices or objects, e.g. connectors, inlet details
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/02—Identification, exchange or storage of information
    • B01L2300/025—Displaying results or values with integrated means
    • B01L2300/028—Graduation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
    • B01L3/5082—Test tubes per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Definitions

  • the present invention relates to a urine test kit used in the detection of viral diseases, especially SARS-CoV-2 virus and its mutants, where the clinical picture of disease can be determined through the detection of the protein and amino acid structures of the virus and their metabolites in urine and to the method of use thereof.
  • the invention relates to a urine test kit applied to determine protein and amino acid structures of the virus and their metabolites in urine using a reactant, foaming the urine and evaluating the foamed urine through a marker in order to detect viral diseases and to the method of use thereof.
  • Viruses are infectious agents that contain their genetic structures, protein structures and amino acid structures, which are the sub-sequences of these protein structures and can only be examined under microscope.
  • the virus causing COVID-19 (SARS-CoV-2) is also an RNA virus with its own genetic structure, protein and amino acid structures.
  • SARS- CoV-2 reproduces rapidly once it enters the body.
  • some metabolic and chemical changes start to occur in the body. Some of these changes may be monitored by blood, urine and similar tests.
  • viral structures, the metabolites of viral structures and some substances forming due to the problems indirectly caused by the virus start to be excreted in the urine.
  • the excretion rate is directly related to the infection ability of the virus, the count of the virus transmitted to an individual, the immune system strength as well as metabolism and other diseases of such individual.
  • kits are known in existing applications; however, the urine-related tests are: standard complete urinalysis, urine culture, examination of urine with strips and urine electrophoresis. These examinations help to detect substances that are excreted in urine and should not be present in normal conditions. However, if the microorganism load that increases especially in viral, bacterial, fungal or parasitic diseases is detected in urine, not all the available urine tests can detect this load. The underlying reason is that urine test devices cannot identify the structures of microorganisms and their metabolites and are not calibrated for this process.
  • An object of the invention is to provide a fast and practical urine test kit that can be used for detecting within seconds the virus load of any patient suffering from a contagious disease that requires instant diagnosis since preliminary diagnosis, final diagnosis and clinical follow up are vital, to separate healthy and sick individuals and to regulate and monitor the diagnosis and treatment processes.
  • This test offers an extremely important advantage to the countries that face challenges in this regard, doctors working on this area and people who want to self-test easily without going to any health institution.
  • This test kit plays a major role in the early detection of the virus in the body and thus, the treatment of the patient and preventing any contact with other living creatures since it is practical and gives fast results.
  • Another object of the invention is to enable patients with or without symptoms to self-test on the spot without going to any health institution and increasing the risk of transmission, and to acquire information within seconds about the presence of virus and the count of viruses being exposed to.
  • Another object of the invention is to enable the infected patients to be alerted immediately to take precautions since the viral density is also detected in a short time.
  • Yet another object of the invention is to make sure that the test kit notifies individuals about viral density rather than simply giving positive or negative results and thus, to enable to refer patients with high viral density, i.e., risk of having a more severe course of disease, to health institutions.
  • Another object of the invention is to eliminate the test load on the health institutions, to prevent the risk of transmission during this process and to reduce the cost of consumables related to analysis devices and the equipment used.
  • Another object of the invention is to provide a result that is easily understandable for everyone by means of the level indicators on the test. For example, when coloring scales are used, the test gives an entirely visual result and even an illiterate person can get an idea about the result.
  • Yet another object of the invention is to prevent the kit used in the invention from requiring any specific space and specific physical conditions. Thus, tests can be performed in any environment.
  • FIGURE 1 is a drawing of urine test according to the invention and its method of use.
  • urine Under normal conditions, urine has a pH of 6 and a density of 1010-1020. It is a light yellow bodily fluid with its unique odor. Normally, urine does not foam or slightly foams, and the resulting foam disappears immediately.
  • the invention will be explained, by way of example, by evaluating the protein structures of the SARS-CoV-2 virus, especially the Serine and Arginine amino acids.
  • the protein structures of the SARS-CoV-2 virus, especially the structure of the Serine and Arginine amino acids serve as an identification for the virus. Such that this structure is composed of Lysine and Glutamine amino acids in Influenza virus.
  • each virus has a unique amino acid structure and a protein structure consisting of these amino acids. This plays an important role in distinguishing viruses from each other.
  • SARS-CoV-2 reproduces rapidly once it enters the body.
  • its proteins and amino acid structures which are the building blocks of these proteins, are excreted from the body either directly or in the form of metabolites via stool, urine and other body fluids. Live and dead viruses can also be excreted in the same manner.
  • Developed countries therefore, try to detect viruses in samples taken from sewers in the fight against SARS-CoV-2 and take advanced health measures in that particular region, accordingly.
  • the tube (20) is selected in terms of shape and size in compliance with the chemical and physical structure of the reactant (30) contained therein.
  • the amount of reactant (30) in the tube (20) and the amount of urine to be placed into the tube (20) are determined according to the chemical and physical phases of the expected reaction.
  • a marker (40) showing the viral load in the body was placed on the tube (20).
  • This marker (40) may be in the form of color scale, number, line, etc.
  • a color scale is used as the marker (40) for sampling. This color scale was placed on the tube (20).
  • the physical structure, cap and the ergonomics of the tube (20) during the testing phase are determined in the method.
  • a urine container (50) that can be used both directly and in a vacuum tube (20) is added to the urine test kit (10) so that the urine can be collected easily.
  • the urine sample taken from an individual to be tested is placed into the urine container (50).
  • Urine is filled up to the level line on the tube (20) and the cap of the tube (20) is closed. This step is not needed in a vacuum tube (20).
  • the vacuum automatically draws sufficient urine amount to the level line.
  • the vacuum tube (20) is produced with its cap closed.
  • the reactant (30) of particulate form in the tube (20) is agitated vigorously for 15 seconds in order to mix it homogeneously in the urine. After fifteen seconds, the tube (20) is placed on a flat surface and approximately ten seconds are allowed to eliminate the foam arising from agitation. After this period, the foam appearing in the tube (20) is the foam occurring due to the chemical reaction caused by the reactant (30).
  • the foam level in the tube (20) is interpreted according to the explanations in the user manual, corresponding to the level on the marker (40), i.e., the color scale, on the tube (20).
  • the invention in summary, relates to a urine test kit (10) used in the detection of viral diseases, especially SARS-CoV-2 virus and its mutants, where the clinical picture of disease can be determined through the detection of the protein and amino acid structures of the virus and their metabolites in urine, and to the using method of it.
  • the urine test kit (10) there are provided the urine container (50) in which the urine sample taken from an individual to be tested is placed and a tube (20) containing the reactant (30) that reacts with the protein and amino acid structures of the virus.
  • a vacuum tube (20) may be used as a tube (20) in the urine test kit (10) so that it can automatically draw urine into its body.
  • This tube (20) may also be filled manually.
  • This marker (40) can be in the form of a color scale for easy interpretation or in the form of a line scale created during the production of the tube (20).
  • Another area on the tube (20) used in the invention is the urine borderline that can be formed at the bottom during the production of the tube (20) and used to determine the level of urine to be filled.
  • the method of using the urine test kit (10) in Figure 1 comprises of placing the urine sample taken from an individual to be tested into the urine container (50), filling the urine up to the urine borderline on the tube (20), mixing the reactant (30) in the particulate form in the tube (20) homogeneously in the urine, reacting the reactant (30) with the urine as a result of mixing, placing the tube (20) on a flat surface after mixing, waiting for the resulting foam due to the effect of reaction to disappear, the foam forming in the tube (20) after the waiting being the foam of the chemical reaction caused by the reactant (30), determining the level of foam in the tube (20) based on the marker (40) on the tube (20) and interpreting the health condition of the individual based on the foam level.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Clinical Laboratory Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne une trousse d'analyse d'urine (10) utilisée dans la détection de maladies virales, en particulier le virus SARS-CoV-2 et ses mutants, le tableau clinique de la maladie pouvant être déterminé par la détection des structures des protéines et des acides aminés du virus et de leurs métabolites dans l'urine, ainsi que sa méthode d'utilisation. Plus précisément, l'invention concerne une trousse d'analyse d'urine (10) appliquée pour déterminer les structures de protéines et d'acides aminés du virus et de leurs métabolites dans l'urine à l'aide d'un réactif (30) afin de détecter les maladies virales, en faisant mousser l'urine et en déterminant le virus et la densité virale chez un individu sur la base du niveau de mousse de l'urine moussée, ainsi que son procédé d'utilisation.
PCT/TR2021/050520 2021-02-17 2021-06-01 Trousse d'analyse d'urine et son mode d'utilisation WO2022177520A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2021/002255A TR202102255A2 (tr) 2021-02-17 2021-02-17 İdrar anali̇z ki̇ti̇ ve kullanim yöntemi̇
TR2021/002255 2021-02-17

Publications (1)

Publication Number Publication Date
WO2022177520A1 true WO2022177520A1 (fr) 2022-08-25

Family

ID=76373913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2021/050520 WO2022177520A1 (fr) 2021-02-17 2021-06-01 Trousse d'analyse d'urine et son mode d'utilisation

Country Status (2)

Country Link
TR (1) TR202102255A2 (fr)
WO (1) WO2022177520A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348207A (en) * 1981-01-29 1982-09-07 Cooper Laboratories, Inc. Method and means for determination of pregnancy
CN111562367A (zh) * 2020-06-15 2020-08-21 郑州方欣生物科技有限责任公司 尿液新型冠状病毒快速检测试剂盒、制备方法及使用方法
US10758761B1 (en) * 2019-08-14 2020-09-01 Phong Duy Bui Method for liquid narcotic medication validation and deactivation
CN111999508A (zh) * 2020-05-15 2020-11-27 上海交通大学 一种诊断标志物及其在covid-19诊断及冠状病毒既往感染检测中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348207A (en) * 1981-01-29 1982-09-07 Cooper Laboratories, Inc. Method and means for determination of pregnancy
US10758761B1 (en) * 2019-08-14 2020-09-01 Phong Duy Bui Method for liquid narcotic medication validation and deactivation
CN111999508A (zh) * 2020-05-15 2020-11-27 上海交通大学 一种诊断标志物及其在covid-19诊断及冠状病毒既往感染检测中的应用
CN111562367A (zh) * 2020-06-15 2020-08-21 郑州方欣生物科技有限责任公司 尿液新型冠状病毒快速检测试剂盒、制备方法及使用方法

Also Published As

Publication number Publication date
TR202102255A2 (tr) 2021-03-22

Similar Documents

Publication Publication Date Title
Fernández-Solà et al. Evidence of apoptosis in alcoholic cardiomyopathy
CN101013137A (zh) 一类检测缺血性修饰白蛋白的试剂盒及其检测方法
CN101025415A (zh) 一种检测尿液中尿酸含量范围的试纸
WO2010141719A2 (fr) Matériaux et procédés de mesure des taux d'oxyde nitrique dans des fluides biologiques
Bader et al. Clinical significance of saliva urea and creatinine levels in patients with chronic kidney disease
Jung et al. Diagnostic significance of different urinary enzymes in patients suffering from chronic renal diseases
WO2017006962A1 (fr) Kit d'examen sanguin, et procédé d'analyse sanguine
CN106191286A (zh) 布鲁氏菌的检测方法、试剂盒及其应用
WO2022177520A1 (fr) Trousse d'analyse d'urine et son mode d'utilisation
Desai et al. Accuracy of urinary dipstick testing for pH manipulation therapy
Aisen et al. A rapid screening test for deficiency of plasma ceruloplasmin and its value in the diagnosis of Wilson's disease
US6852541B2 (en) Rapid assay for testing overall oxidative stress
Mohling et al. Intestinal Permeability and Endometriosis: A pilot investigation
Chida et al. Precision and reliability of stable microbubble test as a predictor of respiratory distress syndrome
CN110618275A (zh) 帕金森病的诊断标志物及其应用
CN104388532A (zh) 一种检测α-L-岩藻糖苷酶含量的试剂盒
CN108872605A (zh) 一种美洲锥虫病的检测试剂盒及其检测方法
CN106257287B (zh) 生长分化因子15评估高血压患者首发脑卒中的新应用
CN104569396A (zh) 肝癌诊断试剂及其用途
RU2279681C2 (ru) Способ экспресс-определения содержания кальция в моче
RU2157528C1 (ru) Способ прогнозирования злокачественных новообразований
Sippy et al. Measurement of free acid in gastric juice by means of indicator paper
Kanehira et al. A pilot study of a simple screening technique for estimation of salivary flow
RU31318U1 (ru) Диагностический тест-набор для оценки состояния печени
CN107561256A (zh) 一种用于泌尿科检查用的医疗器械

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21926965

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE